Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab

被引:5
|
作者
Schargus, Marc [1 ,2 ]
Kopp, Katharina Tatjana [3 ]
Helbig, Constanze [4 ]
Frings, Andreas [1 ]
Winter, Gerhard [3 ]
机构
[1] Heinrich Heine Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Asklepios Hosp Nord Heidberg, Dept Ophthalmol, Hamburg, Germany
[3] Ludwig Maximilians Univ Munchen, Dept Pharm Pharmaceut Technol & Biopharmaceut, Munich, Germany
[4] Coriolis Pharma Res GmbH, Martinsried, Germany
来源
关键词
aflibercept; bevacizumab; brolucizumab; contamination; protein particles; silicone oil; intravitreal injection; INTRAOCULAR-PRESSURE; RANIBIZUMAB; INJECTION; TRAP;
D O I
10.1167/tvst.10.9.21
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. Methods: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. Results: Repackaged bevacizumab showed overall low particle numbers, aflibercept showed high numbers of micrometer sized particles but low nanoparticle numbers, brolucizumab showed low to moderate numbers of micrometer sized particles but high nanoparticle numbers. RMM measurements identified particles in the nanometer range as either proteinaceous or silicon oil; the nature of the other particles was not further evaluated. Conclusions: Repackaged bevacizumab shows no inferior particle quality compared to ready-to-use products. It is relevant to study nanoparticle load of the products as the micrometer-sized particle numbers do not in all cases correlate to nanoparticle counts. Particularly for the high concentration product Beovu (brolucizumab), high nanoparticle numbers were found despite low numbers of micrometer sized particles. Silicone oil droplets did not account for high particle numbers as the measured numbers were low. Translational Relevance: Different side effects are registered in different frequencies with different intravitreal anti-VEGF-drugs and syringes, which are applied by injection by small 30G needles through the sclera directly to the intravitreal cavity. The study of nanoparticles and silicone oil droplets may be able to contribute to narrowing down the causes.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Does Intravitreal Anti-VEGF Therapy with Ranibizumab, Bevacizumab, and Aflibercept Cause Rebound Supranormal Systemic VEGF Levels?
    Frenkel, Ronald
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [2] CONTAMINATION OF ANTI-VEGF DRUGS FOR INTRAVITREAL INJECTION How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?
    Schargus, Marc
    Werner, Benjamin P.
    Geerling, Gerd
    Winter, Gerhard
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (10): : 2088 - 2095
  • [3] Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD
    Schaal, K. B.
    Engler, C.
    Schuett, F.
    Scheuerle, A.
    Dithmar, S.
    OPHTHALMOLOGE, 2008, 105 (06): : 538 - +
  • [4] Issues with Intravitreal Administration of Anti-VEGF Drugs
    Schargus, Marc
    Frings, Andreas
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 897 - 904
  • [5] Clinical pharmacology of intravitreal anti-VEGF drugs
    Fogli, Stefano
    Del Re, Marzia
    Rofi, Eleonora
    Posarelli, Chiara
    Figus, Michele
    Danesi, Romano
    EYE, 2018, 32 (06) : 1010 - 1020
  • [6] Clinical pharmacology of intravitreal anti-VEGF drugs
    Stefano Fogli
    Marzia Del Re
    Eleonora Rofi
    Chiara Posarelli
    Michele Figus
    Romano Danesi
    Eye, 2018, 32 : 1010 - 1020
  • [7] The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
    He, Kuifeng
    Cui, Binbin
    Li, Guangliang
    Wang, Haohao
    Jin, Ketao
    Teng, Lisong
    ONCOTARGETS AND THERAPY, 2012, 5 : 59 - 65
  • [9] Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab
    Hwang, Duck Jin
    Kim, Yong Woo
    Woo, Se Joon
    Park, Kyu Hyung
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (12) : 1580 - 1585
  • [10] Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
    Malik, Deepika
    Tarek, Mohamed
    del Carpio, Javier Caceres
    Ramirez, Claudio
    Boyer, David
    Kenney, M. Cristina
    Kuppermann, Baruch D.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 : 11 - 16